Gland Pharma Limited
GLAND · 543245 · Healthcare · Pharmaceuticals
- Market cap
- Rs 50,717 Cr
- P/E
- 44.88x
- P/B
- 4.90x
- 52W high / low
- Rs 3,171 / Rs 1,573.6
Our computed operating_margin (23.98%) diverges from BSE's own published figure (48.67%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong.
About Gland Pharma
Gland Pharma Limited is listed on the NSE under the symbol GLAND and on the BSE under scrip code 543245. It is classified in the Healthcare sector, industry: Pharmaceuticals. It is a constituent of BSE 500, NIFTY 500, NIFTY Pharma and NIFTY Smallcap 250. The company listed on 20 Nov 2020 and has a face value of Rs 1.
The latest available end-of-day price is Rs 3,074.5 (+0.84% on the day), for a market capitalisation of Rs 50,717 Cr. Trailing P/E is 44.88x and price-to-book is 4.90x. The 52-week range is Rs 1,573.6 to Rs 3,171. The latest price is 94% of the way from the 52-week low to the 52-week high.
Against the 15-company comparison set from the official BSE basic industry Pharmaceuticals, its market capitalisation is 0.5 times the peer median of Rs 1,09,706 Cr, and its P/E of 44.88x compares with a peer median of 36.40x. The comparison set is chosen mechanically from the exchange classification; it is not a ranking.
Latest annual results
For FY26 (year ended 31 Mar 2026), Gland Pharma Limited reported revenue of Rs 6,431 Cr and net profit of Rs 1,027 Cr, with a net margin of 15.98% and earnings per share of Rs 62.35 (consolidated statements).
Year-on-year change: revenue +15.73%; net profit +47.07%; EPS +47.05%. Three-year compound annual growth rate: revenue +20.40%; net profit +9.56%.
At the same date the balance sheet shows total assets of Rs 12,511 Cr, shareholders' equity of Rs 10,358 Cr, total debt of Rs 243 Cr, cash of Rs 3,359 Cr, a debt-to-equity ratio of 0.02 and operating cash flow of Rs 1,031 Cr.
On a trailing-twelve-month basis the filings add up to revenue of Rs 6,725 Cr, net income of Rs 1,129 Cr and a net margin of 16.78%.
Shareholding pattern
In the shareholding pattern for 30 Sept 2026, Gland Pharma Limited's ownership is split: promoters 45.75%; foreign institutional investors (FIIs) 10.36%; domestic institutional investors (DIIs) 33.21%; retail and other shareholders 10.68%.
Compared with the filing for 30 Jun 2026: promoter holding −6.02 percentage points; FII holding +1.62 percentage points; DII holding +2.77 percentage points.
The same filing lists reported promoter pledge of 0.00% and 1,25,667 shareholders on record.
Recent filings and corporate actions
134 BSE corporate announcements were filed by Gland Pharma Limited in the past twelve months; the most frequent category is "Company Update" (99). The most recent is "Conclusion of USFDA Unannounced Inspection at Company''s Formulation Facility at Dundigal, Hyderabad" (Company Update), filed on 23 Oct 2026.
The disclosed corporate-action timeline lists 3 entries: dividend (3). The latest is a dividend (Final Dividend - Rs. - 20.0000) with ex-date 11 Aug 2026.
Figures are raw disclosures from official NSE/BSE and SEBI filings plus mechanically computed ratios, restated in words. This is research data, not investment advice, a rating or a recommendation; DalalOS is not a SEBI-registered investment advisor.
More
Peer comparison
Official BSE basic industry: Pharmaceuticals. Limited to companies within a 0.1x–10x market-cap band.
Edit columns
| Sun Pharmaceutical Industries Limited | Rs 1,761 | Rs 4,22,517 Cr | Rs 62,141 Cr | Rs 12,117 Cr | 34.94x | 15.53% |
| Divi's Laboratories Limited | Rs 9,664 | Rs 2,56,096 Cr | Rs 11,682 Cr | Rs 2,925 Cr | 87.69x | 18.44% |
| Torrent Pharmaceuticals Limited | Rs 4,580 | Rs 1,55,015 Cr | Rs 15,654 Cr | Rs 2,156 Cr | 73.16x | 27.30% |
| Laurus Labs Limited | Rs 2,244 | Rs 1,21,232 Cr | Rs 7,323 Cr | Rs 1,091 Cr | — | 22.38% |
| Zydus Lifesciences Limited | Rs 1,184.4 | Rs 1,18,203 Cr | Rs 29,052 Cr | Rs 4,593 Cr | 26.40x | 17.68% |
| Dr. Reddy's Laboratories Limited | Rs 1,345 | Rs 1,12,308 Cr | Rs 34,353 Cr | Rs 2,760 Cr | 40.02x | 7.84% |
| Cipla Limited | Rs 1,358 | Rs 1,09,706 Cr | Rs 28,855 Cr | Rs 2,854 Cr | 37.86x | 8.83% |
| Mankind Pharma Limited | Rs 2,469.3 | Rs 1,01,982 Cr | Rs 15,705 Cr | Rs 2,264 Cr | 45.45x | 14.78% |
| Aurobindo Pharma Limited | Rs 1,659.9 | Rs 95,511 Cr | Rs 35,625 Cr | Rs 3,711 Cr | 25.94x | 10.53% |
| Lupin Limited | Rs 1,989.9 | Rs 90,988 Cr | Rs 30,442 Cr | Rs 5,551 Cr | 16.44x | 27.89% |
| Glenmark Pharmaceuticals Limited | Rs 2,339 | Rs 66,007 Cr | Rs 18,236 Cr | Rs 1,798 Cr | 36.71x | 15.46% |
| Alkem Laboratories Limited | Rs 5,079 | Rs 60,719 Cr | Rs 15,681 Cr | Rs 2,204 Cr | 28.15x | 16.72% |
| Biocon Limited | Rs 351.9 | Rs 57,346 Cr | Rs 17,638 Cr | Rs 416 Cr | — | 1.78% |
| Abbott India Limited | Rs 26,145 | Rs 55,558 Cr | Rs 7,295 Cr | Rs 1,615 Cr | 34.41x | 35.85% |
| Gland Pharma LimitedThis company | Rs 3,074.5 | Rs 50,717 Cr | Rs 7,045 Cr | Rs 1,129 Cr | 44.88x | 11.57% |
| Median | Rs 2,244 | Rs 1,09,706 Cr | Rs 15,705 Cr | Rs 2,760 Cr | 36.40x | 16.72% |
Peers are selected mechanically from the official BSE industry hierarchy and current market-cap band. This is a comparison set, not a ranking or recommendation.
Companies related to Gland Pharma
Same official industry (Pharmaceuticals)
- Sun Pharmaceutical Industries LimitedSUNPHARMA · Market cap Rs 4,22,517 Cr
- Divi's Laboratories LimitedDIVISLAB · Market cap Rs 2,56,096 Cr
- Torrent Pharmaceuticals LimitedTORNTPHARM · Market cap Rs 1,55,015 Cr
- Laurus Labs LimitedLAURUSLABS · Market cap Rs 1,21,232 Cr
- Zydus Lifesciences LimitedZYDUSLIFE · Market cap Rs 1,18,203 Cr
- Dr. Reddy's Laboratories LimitedDRREDDY · Market cap Rs 1,12,308 Cr
- Cipla LimitedCIPLA · Market cap Rs 1,09,706 Cr
- Mankind Pharma LimitedMANKIND · Market cap Rs 1,01,982 Cr
Other Healthcare companies of a similar market capitalisation
- Alkem Laboratories LimitedALKEM · Market cap Rs 60,719 Cr
- Biocon LimitedBIOCON · Market cap Rs 57,346 Cr
- Fortis Healthcare LimitedFORTIS · Market cap Rs 56,992 Cr
- Abbott India LimitedABBOTINDIA · Market cap Rs 55,558 Cr
- IPCA Laboratories LimitedIPCALAB · Market cap Rs 48,868 Cr
- Anthem Biosciences LimitedANTHEM · Market cap Rs 46,769 Cr
- Ajanta Pharma LimitedAJANTPHARM · Market cap Rs 43,367 Cr
- GlaxoSmithKline Pharmaceuticals LimitedGLAXO · Market cap Rs 42,608 Cr
Companies are grouped mechanically from the exchange classification and listed by market capitalisation. This is a comparison set, not a ranking or recommendation.